Trials / Terminated
TerminatedNCT00686036
Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy
A Randomized, Double-blind, Multicentre, Phase II Controlled Trial Assessing ZACTIMATM (Vandetanib) Against Placebo in Prolonging the Off-treatment Interval in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether treatment with Zactima for up to 18 months will prolong the off-treatment interval in patients who are undergoing intermittent androgen deprivation therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vandetanib | 300 mg orally, once daily for up to 18 months |
| DRUG | Placebo |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2010-04-01
- Completion
- 2010-10-01
- First posted
- 2008-05-29
- Last updated
- 2016-12-21
- Results posted
- 2011-05-24
Locations
11 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00686036. Inclusion in this directory is not an endorsement.